Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

A greater response was observed across multiple clinical endpoints among participants treated with DZP, including 50% less severe disease flares compared to participants on standard of care alone." ...

A woman who spent nine months in hospital needing 'three amputations' feels like she finally has her life back - after getting a bionic leg. Emilia Lindquist, 27, was diagnosed with lupus - an ...

Artificial intelligence is making impressive strides in its ability to read medical images. In a recent test in Britain's ...

There are multiple chapters near you. Select your preferred chapter.

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.